Phathom Pharmaceuticals, Inc.
PHAT
$9.58
$0.404.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 74.27M | 58.30M | 57.58M | 49.50M | 39.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 74.27M | 58.30M | 57.58M | 49.50M | 39.50M |
| Cost of Revenue | 15.10M | 12.00M | 7.65M | 6.19M | 5.04M |
| Gross Profit | 59.18M | 46.31M | 49.94M | 43.31M | 34.47M |
| SG&A Expenses | 55.33M | 54.01M | 48.37M | 51.56M | 85.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.24M | 73.78M | 63.51M | 64.78M | 99.43M |
| Operating Income | -3.97M | -15.48M | -5.93M | -15.27M | -59.92M |
| Income Before Tax | -17.58M | -30.37M | -21.15M | -29.97M | -75.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.58M | -30.37M | -21.15M | -29.97M | -75.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.58M | -30.37M | -21.15M | -29.97M | -75.81M |
| EBIT | -3.97M | -15.48M | -5.93M | -15.27M | -59.92M |
| EBITDA | -3.85M | -15.37M | -5.80M | -15.12M | -59.75M |
| EPS Basic | -0.21 | -0.37 | -0.29 | -0.41 | -1.05 |
| Normalized Basic EPS | -0.13 | -0.23 | -0.18 | -0.26 | -0.65 |
| EPS Diluted | -0.21 | -0.37 | -0.29 | -0.41 | -1.05 |
| Normalized Diluted EPS | -0.13 | -0.23 | -0.18 | -0.26 | -0.65 |
| Average Basic Shares Outstanding | 83.75M | 82.05M | 73.82M | 73.40M | 72.47M |
| Average Diluted Shares Outstanding | 83.75M | 82.05M | 73.82M | 73.40M | 72.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |